[go: up one dir, main page]

WO2008020302A2 - Composés hétéro-aromatiques à base de quinoline - Google Patents

Composés hétéro-aromatiques à base de quinoline Download PDF

Info

Publication number
WO2008020302A2
WO2008020302A2 PCT/IB2007/002382 IB2007002382W WO2008020302A2 WO 2008020302 A2 WO2008020302 A2 WO 2008020302A2 IB 2007002382 W IB2007002382 W IB 2007002382W WO 2008020302 A2 WO2008020302 A2 WO 2008020302A2
Authority
WO
WIPO (PCT)
Prior art keywords
quinolin
methoxy
quinazoline
disorder
preparation
Prior art date
Application number
PCT/IB2007/002382
Other languages
English (en)
Other versions
WO2008020302A3 (fr
Inventor
Christopher John Helal
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of WO2008020302A2 publication Critical patent/WO2008020302A2/fr
Publication of WO2008020302A3 publication Critical patent/WO2008020302A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors.
  • PDE phosphodiesterase
  • the invention also relates to compounds which are selective inhibitors of PDE10.
  • the invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders.
  • CNS central nervous system
  • the invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom.
  • Phosphodiesterases are a class of intracellular enzymes involved in the hydrolysis of the nucleotides cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphates (cGMP) into their respective nucleotide monophosphates.
  • the cyclic nucleotides cAMP and cGMP are synthesized by adenylyl and guanylyl cyclases, respectively, and serve as secondary messengers in several cellular pathways.
  • the cAMP and cGMP function as intracellular second messengers regulating a vast array of intracellular processes particularly in neurons of the central nervous system. In neurons, this includes the activation of cAMP and cGMP-dependent kinases and subsequent phosphorylation of proteins involved in acute regulation of synaptic transmission as well as in neuronal differentiation and survival.
  • the complexity of cyclic nucleotide signaling is indicated by the molecular diversity of the enzymes involved in the synthesis and degradation of cAMP and cGMP. There are at least ten families of adenylyl cyclases, two of guanylyl cyclases, and eleven of phosphodiesterases.
  • different types of neurons are known to express multiple isozymes of each of these classes, and there is good evidence for compartmentalization and specificity of function for different isozymes within a given neuron.
  • a principal mechanism for regulating cyclic nucleotide signaling is by phosphodiesterase-catalyzed cyclic nucleotide catabolism.
  • PDEs encoded by 21 different genes. Each gene typically yields multiple splice variants that further contribute to the isozyme diversity.
  • the PDE families are distinguished functionally based on cyclic nucleotide substrate specificity, mechanism(s) of regulation, and sensitivity to inhibitors.
  • PDEs are differentially expressed throughout the organism, including in the central nervous system. As a result of these distinct enzymatic activities and localization, different PDEs' isozymes can serve distinct physiological functions.
  • PDE10 is identified as a unique family based on primary amino acid sequence and distinct enzymatic activity. Homology screening of EST databases revealed mouse PDE10A as the first member of the PDE10 family of PDEs (Fujishige et al., J. Biol. Chem. 274:18438- 18445, 1999; Loughney, K. et al., Gene 234:109-117, 1999). The murine homologue has also been cloned (Soderling, S. et al., Proc. Natl. Acad. Sci.
  • mice PDE10A1 is a 779 amino acid protein that hydrolyzes both cAMP and cGMP to AMP and GMP, respectively.
  • the PDE 10 family of polypeptides shows a lower degree of sequence homology as compared to previously identified PDE families and has been shown to be insensitive to certain inhibitors that are known to be specific for other PDE families.
  • PDE10 also is uniquely localized in mammals relative to other PDE families. mRNA for PDE10 is highly expressed only in testis and brain (Fujishige, K. et al., Eur J Biochem. 266:1118-1127, 1999; Soderling, S. et al., Proc. Natl. Acad. Sci. 96:7071-7076, 1999;
  • PDE inhibitors A variety of therapeutic uses for PDE inhibitors has been reported including obtrusive lung disease, allergies, hypertension, angina, congestive heart failure, depression and erectile dysfunction (WO 01/41807 A2, incorporated herein by reference).
  • United States Patent Application Publication No. 2003/0032579 discloses a method for treating certain neurologic and psychiatric disorders with the selective PDE10 inhibitor papaverine.
  • the method relates to psychotic disorders such as schizophrenia, delusional disorders and drug-induced psychosis; to anxiety disorders such as panic and obsessive-compulsive disorder; and to movement disorders including Parkinson's disease and Huntington's disease.
  • WO2005/120514 discloses a method for treating obesity-related and metabolic syndrome-related conditions by administering a PDE10 inhibitor.
  • the present invention provides for compounds of formula I or pharmaceutical salts thereof,
  • HET 1 is selected from the group consisting of a monocyclic heteroaryl and a bicyclic heteroaryl, wherein said HET 1 may optionally be substituted with at least one R 1 ;
  • B 1 and B 2 are adjacent atoms in Het 1 wherein B 2 is carbon and B 1 is nitrogen.
  • X, Y and Z are each independently N or CR 5 , with the provisos that at least one of X, Y and Z must be CR 5 and when R 4 is O, R 4 is divalent and Z is NR 10 ; wherein each R 1 is independently selected from a group consisting of halogen, hydroxyl, cyano, (CrC 8 )alkyl, (C 2 - C 8 )alkenyl, (C 2 -C 8 )alkynyl, (Ci-C 8 )alkoxy, (C r C 8 )haloalkyl, (C- ⁇ -C 8 )haloalkoxy, (C 3 -C 8 )cycloalkyl, (5-12 membered)heterocycloalkyl, (CrC 8 )alkylthio, - NR 8 R 9 , -C(O)
  • NR 8 R 9 -NHCOR 8 , -OH, (C 6 -C 12 )aryl, (5-12 membered)heteroaryl, (C r C 8 )alkyl, (C r C 8 )alkoxy, (Ci-C 6 )haloalkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 2 -C 6 )alkenyloxy or (C 3 -C 8 )cycloalkyl;
  • R 4 is hydrogen, O, halogen, cyano, -NR 8 R 9 , -C(O)R 8 , (C r C 6 )alkyl, (C r C 6 )alkoxy, (C 3 -
  • C 12 cycloalkyl, (C r C 6 )haloalkyl, (4-12 membered)heterocycloalkyl, (C 6 -Ci 2 )aryl, -(5-12 membered)heterocycloalkyl-(C 6 -C 12 )aryl, (5-12 membered)heteroaryl, (5-12 membered)heterocycloalkyloxy, (C 6 -Ci 2 )aryloxy, (5-12 membered)heteroaryloxy, -(C 6 -
  • Ci 2 aryl-(Ci-C 6 )alkyl, or -(5-12 membered)heteroaryl-(Ci-C 6 )alkyl, wherein when R 4 is alkyl, alkoxy, cycloalkyl, haloalkyl, heterocycloalkyl, aryl, -heterocycloalkyl-aryl, heteroaryl, heterocycloalkyloxy, aryloxy, heteroaryl, heteroaryloxy, -aryl-alkyl, or -heteroaryl-alkyl, it may be optionally substituted by at least one R 7 ;
  • R 5 is independently hydrogen, halogen, -NR 8 R 9 , hydroxyl, (C r C 8 )alkyl, (CrC 8 )alkoxy, (C r C 8 )haloalkyl, (C r C 8 )hydroxyalkyl or (C 3 -C 8 )cycloalkyl; -A-
  • each R 7 is independently hydrogen, halogen, hydroxy, cyano, -COOH, - COOR 8 , -CONR 8 R 9 , -COR 8 , -NR 8 R 9 , -NHCOR 8 , -HNCOOR 8 , -HNCONHR 8 , (C r C 8 )alkyl, (C r C 8 )alkoxy, (C r C 6 )haloalkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 2 -C 6 )alkenyloxy, (C 3 - C 8 )cycloalkyl, (C r C 8 )hydroxyalkyl, (C 1 -C 8 )alkoxy-(C 1 -C 8 )alkyl, (C 3 -C 8 )hydroxycycloalkyl, (C 3 - C 8 )cycloalkoxy, -(C r)
  • R 10 is independently hydrogen, (C r C 8 )alkyl, (C r C 8 )haloalkyl, (Ci-C 8 )hydroxyalkyl or (C 3 -C 8 )cycloalkyl; n is 1 , 2 or 3.
  • HET 1 is selected from the group consisting of:
  • HET 1 is selected from the group consisting of
  • R is a phenyl, pyridinyl or a heterocycloalkyl having the formula:
  • R 6 is hydrogen, -COOR 8 , -CONR 8 R 9 , -COR 8 , -NR 8 R 9 , -NHCOR 8 , -OH, -HNCOOR 8 , CN, -HNCONHR 8 , (C r C 6 )alkyl or (C 1 -C 6 ) alkoxy; R 7 is defined above, and p is O or 1.
  • one or two of X, Y and Z are nitrogen. In another embodiment of the present invention, X and Z are nitrogen and Y is CH. In another embodiment of the present invention, the compound has the formula 1B:
  • R 3 is (CrC 8 )alkoxy.
  • HET 1 is selected from:
  • R 4 is a phenyl, pyridinyl or a heterocycloalkyl having the formula:
  • R 6 is hydrogen, -COOR 8 , -CONR 8 R 9 , -COR 8 , -NR 8 R 9 , -NHCOR 8 , -OH, -HNCOOR 8 , -CN, -HNCONHR 8 , (C r C 6 )alkyl or (C r C 6 )alkoxy; wherein R 7 is defined above; and p is 1.
  • R 4 is the heterocycloalkyl of Formula IA wherein R 6 is hydrogen and R 7 is phenyl.
  • X and Z are nitrogen and Y is CH.
  • Compounds of the Formula I may have optical centers and therefore may occur in different enantiomeric and diastereomeric configurations.
  • the present invention includes all enantiomers, diastereomers, and other stereoisomers of such compounds of the Formula I, as well as racemic compounds and racemic mixtures and other mixtures of stereoisomers thereof.
  • Pharmaceutically acceptable salts of the compounds of Formula I include the acid addition and base salts thereof.
  • Suitable acid addition salts are formed from acids which form non-toxic salts.
  • Examples include, but are not limited to, the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mandelates mesylate, methylsulphate, naphthylate, 2- napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, salicylate, saccharate, stearate
  • Suitable base salts are formed from bases which form non-toxic salts. Examples include, but are not limited to, the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
  • Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
  • suitable salts see Handbook of Pharmaceutical Salts: Properties,
  • compositions of Formula I may be prepared by one or more of three methods:
  • 'crystalline' refers to a solid phase in which the material has a regular ordered internal structure at the molecular level and gives a distinctive X-ray diffraction pattern with defined peaks. Such materials when heated sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterised by a phase change, typically first order ('melting point').
  • the compounds of the invention may also exist in unsolvated and solvated forms.
  • the term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
  • the term 'hydrate' is employed when said solvent is water.
  • a currently accepted classification system for organic hydrates is one that defines isolated site, channel, or metal-ion coordinated hydrates - see Polymorphism in Pharmaceutical Solids by K. R. Morris (Ed. H. G. Brittain, Marcel Dekker, 1995).
  • Isolated site hydrates are ones in which the water molecules are isolated from direct contact with each other by intervening organic molecules. In channel hydrates, the water molecules lie in lattice channels where they are next to other water molecules.
  • the compounds of the invention include compounds of Formula I as hereinbefore defined, including all polymorphs and crystal habits thereof, prodrugs and isomers thereof (including optical, geometric and tautomeric isomers) as hereinafter defined and isotopically- labeled compounds of Formula I.
  • 'prodrugs' of the compounds of Formula I are also within the scope of the invention.
  • certain derivatives of compounds of Formula I which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of Formula I having the desired activity, for example, by hydrolytic cleavage.
  • Such derivatives are referred to as 'prodrugs'.
  • Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug Design, Pergamon Press, 1987 (Ed. E. B. Roche, American Pharmaceutical Association).
  • Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of Formula I with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985).
  • prodrugs in accordance with the invention include, but are not limited to, (i) where the compound of Formula I contains a carboxylic acid functionality
  • metabolites of compounds of Formula I that is, compounds formed in vivo upon administration of the drug.
  • Some examples of metabolites in accordance with the invention include, but are not limited to,
  • Compounds of Formual I having a nitrogen atom in a tertiary amine functional group may be further substituted with oxygen (i.e., an N-oxide);
  • Compounds of Formula I containing one or more asymmetric carbon atoms can exist as two or more stereoisomers.
  • a compound of Formula I contains an alkenyl or alkenylene group
  • geometric cisltrans (or Z/E) isomers are possible.
  • structural isomers are interconvertible via a low energy barrier, tautomeric isomerism ('tautomerism') can occur.
  • Cisltrans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.
  • enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).
  • HPLC high pressure liquid chromatography
  • the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of Formula I contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid.
  • a suitable optically active compound for example, an alcohol, or, in the case where the compound of Formula I contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid.
  • the resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to
  • the first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts.
  • the second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer. While both of the crystal forms present in a racemic mixture have identical physical properties, they may have different physical properties compared to the true racemate.
  • Racemic mixtures may be separated by conventional techniques known to those skilled in the art - see, for example, Stereochemistry of Organic Compounds by E. L. EHeI and S. H. Wilen (Wiley, 1994).
  • the present invention includes all pharmaceutically acceptable isotopically-labelled compounds of Formula I wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.
  • isotopes suitable for inclusion in the compounds of the invention include, but are not limited to, isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 CI, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 0, 17 O and 18 O, phosphorus, such as 32 P, and sulphur, such as 35 S.
  • isotopically-labelled compounds of Formula I for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
  • substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Isotopically-labeled compounds of Formula I can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically- labeled reagent in place of the non-labeled reagent previously employed.
  • Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 O, d 6 -acetone, d 6 - DMSO.
  • Specific embodiments of the present invention include the compounds exemplified in the Examples below and their pharmaceutically acceptable salts, complexes, solvates, polymorphs, steroisomers, metabolites, prodrugs, and other derivatives thereof;
  • This invention also pertains to a pharmaceutical composition for treatment of certain psychotic disorders and conditions such as schizophrenia, delusional disorders and drug induced psychosis; to anxiety disorders such as panic and obsessive-compulsive disorder; and to movement disorders including Parkinson's disease and Huntington's disease, comprising an amount of a compound of formula I effective in inhibiting PDE 10.
  • this invention relates to a pharmaceutical composition for treating psychotic disorders and condition such as schizophrenia, delusional disorders and drug induced psychosis; anxiety disorders such as panic and obsessive-compulsive disorder; and movement disorders including Parkinson's disease and Huntington's disease, comprising an amount of a compound of formula I effective in treating said disorder or condition.
  • psychotic disorders and condition such as schizophrenia, delusional disorders and drug induced psychosis
  • anxiety disorders such as panic and obsessive-compulsive disorder
  • movement disorders including Parkinson's disease and Huntington's disease
  • Examples of psychotic disorders that can be treated according to the present invention include, but are not limited to, schizophrenia, for example of the paranoid, disorganized, catatonic, undifferentiated, or residual type; schizophreniform disorder; schizoaffective disorder, for example of the delusional type or the depressive type; delusional disorder; substance-induced psychotic disorder, for example psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; and personality disorder of the schizoid type.
  • Examples of movement disorders that can be treated according to the present invention include but are not limited to selected from Huntington's disease and dyskinesia associated with dopamine agonist therapy, Parkinson's disease, restless leg syndrome, and essential tremor.
  • Other disorders that can be treated according to the present invention are obsessive/compulsive disorders, Tourette's syndrome and other tic disorders.
  • this invention relates to a method for treating an anxiety disorder or condition in a mammal which method comprises administering to said mammal an amount of a compound of formula I effective in inhibiting PDE 10.
  • This invention also provides a method for treating an anxiety disorder or condition in a mammal which method comprises administering to said mammal an amount of a compound of formula I effective in treating said disorder or condition.
  • anxiety disorders examples include, but are not limited to, panic disorder; agoraphobia; a specific phobia; social phobia; obsessive-compulsive disorder; post-traumatic stress disorder; acute stress disorder; and generalized anxiety disorder.
  • This invention further provides a method of treating a drug addiction, for example an alcohol, amphetamine, cocaine, or opiate addiction, in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula I effective in treating drug addiction.
  • a drug addiction for example an alcohol, amphetamine, cocaine, or opiate addiction
  • This invention also provides a method of treating a drug addiction, for example an alcohol, amphetamine, cocaine, or opiate addiction, in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula I effective in inhibiting PDE10.
  • a drug addiction for example an alcohol, amphetamine, cocaine, or opiate addiction
  • a “drug addiction”, as used herein, means an abnormal desire for a drug and is generally characterized by motivational disturbances such a compulsion to take the desired drug and episodes of intense drug craving.
  • This invention further provides a method of treating a disorder comprising as a symptom a deficiency in attention and/or cognition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula I effective in treating said disorder.
  • This invention also provides a method of treating a disorder or condition comprising as a symptom a deficiency in attention and/or cognition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula I effective in inhibiting PDE10.
  • This invention also provides a method of treating a disorder or condition comprising as a symptom a deficiency in attention and/or cognition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula I effective in treating said disorder or condition.
  • deficiency in attention and/or cognition refers to a subnormal functioning in one or more cognitive aspects such as memory, intellect, or learning and logic ability, in a particular individual relative to other individuals within the same general age population.
  • Deficiency in attention and/or cognition also refers to a reduction in any particular individual's functioning in one or more cognitive aspects, for example as occurs in age-related cognitive decline.
  • disorders that comprise as a symptom a deficiency in attention and/or cognition are dementia, for example Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial tumors or cerebral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia; delirium; amnestic disorder; post-traumatic stress disorder; mental retardation; a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression; attention-deficit/hyperactivity disorder; and age-related cognitive decline.
  • dementia for example Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial tumors or cerebral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia
  • delirium amnestic disorder
  • post-traumatic stress disorder mental retardation
  • a learning disorder for example reading disorder, mathematics disorder, or a disorder of written expression
  • attention-deficit/hyperactivity disorder and age
  • This invention also provides a method of treating a mood disorder or mood episode in a mammal, including a human, comprising administering to said mammal an amount of a compound of formula I effective in treating said disorder or episode.
  • Th is invention also provides a method of treating a mood disorder or mood episode in a mammal, including a human, comprising administering to said mammal an amount of a compound of formula I effective in inhibiting PDE10.
  • mood disorders and mood episodes that can be treated according to the present invention include, but are not limited to, major depressive episode of the mild, moderate or severe type, a manic or mixed mood episode, a hypomanic mood episode; a depressive episode with atypical features; a depressive episode with melancholic features; a depressive episode with catatonic features; a mood episode with postpartum onset; post- stroke depression; major depressive disorder; dysthymic disorder; minor depressive disorder; premenstrual dysphoric disorder; post-psychotic depressive disorder of schizophrenia; a major depressive disorder superimposed on a psychotic disorder such as delusional disorder or schizophrenia; a bipolar disorder, for example bipolar I disorder, bipolar Il disorder, and cyclothymic disorder.
  • This invention further provides a method of treating a neurodegenerative disorder or condition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula I effective in treating said disorder or condition.
  • This invention further provides a method of treating a neurodegenerative disorder or condition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula I effective in inhibiting PDE10.
  • a neurodegenerative disorder or condition refers to a disorder or condition that is caused by the dysfunction and/or death of neurons in the central nervous system.
  • the treatment of these disorders and conditions can be facilitated by administration of an agent which prevents the dysfunction or death of neurons at risk in these disorders or conditions and/or enhances the function of damaged or healthy neurons in such a way as to compensate for the loss of function caused by the dysfunction or death of at-risk neurons.
  • the term "neurotrophic agent” as used herein refers to a substance or agent that has some or all of these properties.
  • neurodegenerative disorders and conditions that can be treated according to the present invention include, but are not limited to, Parkinson's disease; Huntington's disease; dementia, for example Alzheimer's disease, multi-infarct dementia, AIDS-related dementia, and Fronto temperal Dementia; neurodegeneration associated with cerebral trauma; neurodegeneration associated with stroke, neurodegeneration associated with cerebral infarct; hypoglycemia-induced neurodegeneration; neurodegeneration associated with epileptic seizure; neurodegeneration associated with neurotoxin poisoning; and multi-system atrophy.
  • the neurodegenerative disorder or condition comprises neurodegeneration of striatal medium spiny neurons in a mammal, including a human.
  • the neurodegenerative disorder or condition is Huntington's disease.
  • This invention also provides a method of treating a disorder selected from psychotic disorders, delusional disorders and drug induced psychosis; anxiety disorders, movement disorders, obesity, mood disorders, and neurodegenerative disorders, which method comprises administering an amount of a compound of formula I effective in treating said disorder.
  • This invention also provides a method of treating disorders selected from the group consisting of: dementia, Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial tumors or cerebral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia; delirium; amnestic disorder; post-traumatic stress disorder; mental retardation; a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression; attention-deficit/hyperactivity disorder; age-related cognitive decline, major depressive episode of the mild, moderate or severe type; a manic or mixed mood episode; a hypomanic mood episode; a depressive episode with atypical features; a depressive episode with melancholic features; a depressive episode with catatonic features; a mood episode with postpartum onset; post-stroke depression; major depressive disorder; dysthymic disorder; minor depressive disorder; premenstrual dysphoric disorder; post-psychotic depressive disorder of schizophrenia; a major depressive disorder
  • This invention also provides a method of treating psychotic disorders, delusional disorders and drug induced psychosis; anxiety disorders, movement disorders, mood disorders, neurodegenerative disorders, obesity, and drug addiction which method comprises administering an amount of a compound of formula I effective in inhibiting PDE 10.
  • alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties.
  • alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, and t-butyl.
  • alkenyl as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above. Examples of alkenyl include, but are not limited to, ethenyl and propenyl.
  • alkynyl as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above. Examples of alkynyl groups include, but are not limited to, ethynyl and 2-propynyl.
  • alkoxy refers to an alkyl, groups linked to an oxygen atom.
  • alkylthio as used herein, unless otherwise indicated, employed herein alone or as part of another group includes any of the above alkyl groups linked through a sulfur atom.
  • halogen or "halo” as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine.
  • haloalkyl refers to at least one halo group, linked to an alkyl group. Examples, of haloalkyl groups include, but are not limited, to trifluoromethyl, trifluoroethyl, difluoromethyl and fluoromethyl groups.
  • cycloalkyl includes non- aromatic saturated cyclic alkyl moieties wherein alkyl is as defined above.
  • examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • aryl as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl, naphthyl, indenyl, and fluorenyl. "Aryl” encompasses fused ring groups wherein at least one ring is aromatic.
  • heterocyclic refers to non-aromatic cyclic groups containing one or more heteroatoms, prefereably from one to four heteroatoms, each preferably selected from oxygen, sulfur and nitrogen.
  • heterocyclic groups of this invention can also include ring systems substituted with one or more oxo moieties.
  • non-aromatic heterocyclic groups are aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl, piperazinyl, 1 ,2,3,6-tetrahydropyridinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholino, thiomorpholino, thioxanyl, pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1 ,3- dioxolanyl, pyrazolinyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.
  • heteroaryl refers to aromatic groups containing one or more heteroatoms (preferably oxygen, sulfur and nitrogen), preferably from one to four heteroatoms.
  • a multicyclic group containing one or more heteroatoms wherein at least one ring of the group is aromatic is a "heteroaryl” group.
  • the heteroaryl groups of this invention can also include ring systems substituted with one or more oxo moieties.
  • Heteroaryl groups containing a tertiary nitrogen may also be further substituted with oxygen (i.e., an N-oxide).
  • heteroaryl groups are pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benz ⁇ thiophenyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl,
  • substituents refers to from one to the maximum number of substituents possible based on the number of available bonding sites.
  • all the foregoing groups derived from hydrocarbons may have up to about 1 to about 20 carbon atoms (e.g. C 1 -C 2O alkyl, C 2 -C 2O alkenyl, C 3 -C 20 cycloalkyl, 3-20 membered heterocycloalkyl; C 6 -C 2O aryl, 5-20 membered heteroaryl, etc.) or 1 to about 15 carbon atoms (e.g., CrCi 5 alkyl, C 2 -Ci 5 alkenyl, C 3 -C 15 cycloalkyl, 3-15 membered heterocycloalkyl, C 6 -Ci 5 aryl, 5-15 membered heteroaryl, etc.) , or 1 to about 12 carbon atoms, or 1 to about 8 carbon atoms, or 1 to about 6 carbon atoms.
  • carbon atoms e.g. C 1 -C 2O alkyl, C 2 -C 2O alkenyl, C 3 -
  • Neurotoxins poisoning refers to poisoning caused by a neurotoxin.
  • a neurotoxin is any chemical or substance that can cause neural death and thus neurological damage.
  • An example of a neurotoxin is alcohol, which, when abused by a pregnant female, can result in alcohol poisoning and neurological damage known as Fetal Alcohol Syndrome in a newborn.
  • Other examples of neurotoxins include, but are not limited to, kainic acid, domoic acid, and acromelic acid; certain pesticides, such as DDT; certain insecticides, such as organophosphates; volatile organic solvents such as hexacarbons (e.g. toluene); heavy metals (e.g.
  • selective PDE10 inhibitor refers to a substance, for example an organic molecule, that effectively inhibits an enzyme from the PDE10 family to a greater extent than enzymes from the PDE 1-9 families or PDE11 family.
  • a selective PDE10 inhibitor is a substance, for example an organic molecule, having a Ki for inhibition of PDE10 that is less than or about one-tenth the Kj that the substance has for inhibition of any other PDE enzyme. In other words, the substance inhibits PDE10 activity to the same degree at a concentration of about one-tenth or less than the concentration required for any other PDE enzyme.
  • a substance is considered to effectively inhibit PDE10 activity if it has a K] of less than or about 10 ⁇ M, preferably less than or about 0.1 ⁇ M.
  • a "selective PDE10 inhibitor” can be identified, for example, by comparing the ability of a substance to inhibit PDE10 activity to its ability to inhibit PDE enzymes from the other PDE families. For example, a substance may be assayed for its ability to inhibit PDE10 activity, as well as PDE1A, PDE1B, PDE1C, PDE2, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5, PDE6, PDE7, PDE8, PDE9, and PDE11.
  • treating refers to reversing, alleviating, or inhibiting the progress of the disorder to which such term applies, or one or more symptoms of the disorder.
  • the term also encompasses, depending on the condition of the patient, preventing the disorder, including preventing onset of the disorder or of any symptoms associated therewith, as well as reducing the severity of the disorder or any of its symptoms prior to onset.
  • Treating refers also to preventing a recurrence of a disorder.
  • treating schizophrenia, or schizophreniform or schizoaffective disorder also encompasses treating one or more symptoms (positive, negative, and other associated features) of said disorders, for example treating, delusions and/or hallucination associated therewith.
  • symptoms of schizophrenia and schizophreniform and schizoaffec ive disorders include disorganized speech, affective flattening, alogia, anhedonia, inappropriate affect, dysphoric mood (in the form of, for example, depression, anxiety or anger), and some indications of cognitive dysfunction.
  • mammal refers to any member of the class “Mammalia”, including, but not limited to, humans, dogs, and cats.
  • the compound of the invention may be administered either alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses.
  • suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
  • the pharmaceutical compositions formed thereby can then be readily administered in a variety of dosage forms such as tablets, powders, lozenges, liquid preparations, syrups, injectable solutions and the like.
  • These pharmaceutical compositions can optionally contain additional ingredients such as flavorings, binders, excipients and the like.
  • the compound of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g. intravenous, intramuscular or subcutaneous), transdermal (e.g. patch) or rectal administration, or in a form suitable for administration by inhalation or insufflation.
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycolate); or wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium phosphate
  • lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium starch glycolate
  • wetting agents
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol); and preservatives (e.g. methyl or propyl p-hydroxybenzoates or sorbic acid).
  • suspending agents e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats
  • emulsifying agents e.g. lecithin or acacia
  • non-aqueous vehicles e.g. almond oil, oily esters or ethyl alcohol
  • preservatives e.g
  • the composition may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion.
  • Formulations for injection may be presented in unit dosage form, e.g. in ampules or in multi-dose containers, with an added preservative. They may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • a product solution When a product solution is required, it can be made by dissolving the isolated inclusion complex in water (or other aqueous medium) in an amount sufficient to generate a solution of the required strength for oral or parenteral administration to patients.
  • the compounds may be formulated for fast dispersing dosage forms (fddf), which are designed to release the active ingredient in the oral cavity. These have often been formulated using rapidly soluble gelatin-based matrices. These dosage forms are well known and can be used to deliver a wide range of drugs. Most fast dispersing dosage forms utilize gelatin as a carrier or structure-forming agent. Typically, gelatin is used to give sufficient strength to the dosage form to prevent breakage during removal from packaging, but once placed in the mouth, the gelatin allows immediate dissolution of the dosage form. Alternatively, various starches are used to the same effect.
  • the compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
  • rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compound of the invention is conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlor
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the pressurized container or nebulizer may contain a solution or suspension of the active compound.
  • Capsules and cartridges made e.g. from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • Aerosol formulations for treatment of the conditions referred to above are preferably arranged so that each metered dose or "puff' of aerosol contains about 20 mg to about 1000 mg of the compound of the invention.
  • the overall daily dose with an aerosol will be within the range of about 100 mg to about 10 mg.
  • Administration may be several times daily, e.g. 2, 3, 4 or 8 times, giving for example, 1 , 2 or 3 doses each time.
  • a proposed daily dose of the compound of the invention for oral, parenteral, rectal or buccal administration to the average adult human for the treatment of the conditions referred to above is from about 0.01 mg to about 2000 mg, preferably from about 0.1 mg to about 200 mg of the active ingredient of formula I per unit dose which could be administered, for example, 1 to 4 times per day.
  • Assay methods are available to screen a substance for inhibition of cyclic nucleotide hydrolysis by the PDE 10 and the PDEs from other gene families.
  • the cyclic nucleotide substrate concentration used in the assay is 1/3 of the K m concentration, allowing for comparisons of IC 50 values across the different enzymes.
  • PDE activity is measured using a Scintillation Proximity Assay (SPA)-based method as previously described (Fawcett et al., 2000).
  • SPA Scintillation Proximity Assay
  • PDE inhibitors The effect of PDE inhibitors is determined by assaying a fixed amount of enzyme (PDEs 1-11) in the presence of varying substance concentrations and low substrate, such that the IC 50 approximates the Ki (cGMP or cAMP in a 3:1 ratio unlabelled to [ 3 H]-Iabeled at a concentration of 1/3 Km). ).
  • the final assay volume is made up to 100 ⁇ l with assay buffer [50 mM Tris-HCI pH 7.5, 8.3 mM MgCI 2 , 1 mg/ml bovine serum albumin].
  • Reactions are initiated with enzyme, incubated for 30-60 min at 30°C to give ⁇ 30% substrate turnover and terminated with 50 ⁇ l yttrium silicate SPA beads (Amersham) (containing 3 mM of the respective unlabelled cyclic nucleotide for PDEs 9 and 11). Plates are re-sealed and shaken for 20 min, after which the beads were allowed to settle for 30 minutes in the dark and then counted on a TopCount plate reader (Packard, Meriden, CT). Radioactivity units can be converted to percent activity of an uninhibited control (100%), plotted against inhibitor concentration and inhibitor IC 50 values can be obtained using the "Fit Curve' Microsoft Excel extension.
  • Step 1 of Scheme 1 is a nucleophilic displacement of a chloride with an amine.
  • Step 2 of Scheme 1 is a dealkylation reaction.
  • Step 3 of Scheme 1 is an alkylation reaction.
  • Step 1 of Scheme 2 is a Suzuki coupling reaction.
  • a palladium catalyst such as Pd 2 (dba) 3 , tricyclohexylphosphine, and cesium carbonate in dioxane at about 100 0 C affords compound 2.
  • Step 2 of Scheme 2 is a dealkylation reaction.
  • Step 3 of Scheme 1 is an alkylation reaction.
  • Step 1 of Scheme 3 is a reductive dehalogenation. Exposure of 6,7-dimethoxy-2,4- dichloroquinazoline and palladium on carbon (about 10%) in a solvent such as methanol and in the presence of a base such as triethylamine to a hydrogen atmosphere, from about 10 to 60 psi, where about 40 psi is preferred, at about room temperature, affords compound 2.
  • Step 2 of Scheme 3 is a dealkylation reaction.
  • Step 3 of Scheme 1 is an alkylation reaction.
  • Step 1 of Scheme 4 is a heterocyclization reaction.
  • a formyl source such as formamidine acetate in a solvent such as ethylene glycol monomethylether at about 13O 0 C for about 24 h affords compound 3.
  • Step 2 of Scheme 4 is a nucleophilic aromatic substitution reaction.
  • Step 3 of Scheme 4 is a dehydrative chlorination.
  • Step 4 of Scheme 4 is a Suzuki coupling reaction.
  • Treatment of compound 5 with an aryl or heteroaryl boronic acid or boronate or dialkylborane, a palladium catalyst such as Pd 2 (dba) 3 , tricyclohexylphosphine, and cesium carbonate in dioxane at about 100 0 C affords compound 6.
  • Step 5 of Scheme 4 is a dealkylation reaction.
  • Step 6 of Scheme 4 is an alkylation reaction.
  • Step 2 of Scheme 5 is an esterification.
  • Step 3 of Scheme 5 is an alkylation reaction.
  • Step 4 of Scheme 5 is a nitro reduction to an amine.
  • Step 5 of Scheme 5 is a hydrolysis.
  • Step 6 of Scheme 5 is a heterocycle forming reaction.
  • Step 7 of Scheme 5 is a dehydrative chlorination.
  • Step 8 of Scheme 5 is A) a Suzuki coupling reaction.
  • Treatment of compound 9 with an aryl or heteroaryl boronic acid or boronate or dialkylborane, a palladium catalyst such as Pd 2 (dba) 3 , tricyclohexylphosphine, and cesium carbonate in dioxane at about 100 0 C affords compound 10; or B) a nucleophilic displacement of a chloride with an amine.
  • Step 9 of Scheme 5 is a dealkylation reaction.
  • Step 10 of Scheme 5 is an alkylation reaction.
  • Step 11 of Scheme 5 is a heterocycle forming reaction.
  • Step 1 of Scheme 6 is an amide forming reaction.
  • Step 2 of Scheme 6 is a heterocycle forming reaction.
  • Treatment of compound 3 with triethyl orthoformate and anhydrous hydrogen chloride in N-methylpyrolidinone at about 120 0 C for about 24 h affords compound 4.
  • Step 3 of Scheme 6 is a dealkylation reaction.
  • Step 4 of Scheme 6 is an alkylation reaction.
  • a diazodicarboxylate such as ditertbutyl azodicarboxylate or diethylazodicarboxylate
  • triphenylphosphine in a solvent such as THF
  • Preparation 2 7-methoxy-4-(3-phenylpiperidin-1 -yl)quinazolin-6-ol: Preparation 1 (2.8 g, 8 mmol) was treated with L-methionine (1.43 g, 9.6 mmol) in methanesulfonic acid (40 mL). The mixture was heated to 120 0 C for 2 h, 14O 0 C for 5 h, then 145 0 C for 1 h. The mixture was poured onto ice, the pH was made basic by using sodium hydroxide (pH ca. 8-9), and the mixture was extracted with chloroform.
  • Preparation 3 7-methoxy-4-(3-phenylpiperidin-1-yl)-6-(prop-2-vnyloxy)quinazoline: A mixture of Preparation 2 (500 mg, 1.49 mmol), propargyl bromide (80% in toluene, 0.25 mL, 2.24 mmol) and cesium carbonate (1g, 3 mmol) in DMSO (10 mL) were stirred for 24 h. The mixture was diluted with ethylacetate (100 mL) and n-butanol (5 mL), was washed with water and brine, was dried over magnesium sulfate, was filtered, and was concentrated. Purification by silica gel chromatography afforded 355 mg (64% yield) of the title compound; MS (AP/CI): 374.5 (M+H)+.
  • Example 1 7-methoxy-4-(3-pheny ) piperidin-1-yl)-6-(2-quinolin-2- ylethoxy)quinazoline: Di-tertbutyl azodicarboxylate (92 mg, 0.4 mmol) was mixed with triphenylphosphine (131 mg, 0.5 mmol) in THF (2 mL) at room temperature for 10 min. 3-(1- Preparation 2 (67 mg, 0.2 mmol) was added followed by 2-(quinolin-2-yl)ethanol (138 mg, 0.8 mmol) and the solution was stirred at room temperature for 24 h.
  • the reaction mixture was diluted with ethyl acetate, was washed with aqueous sodium bicarbonate, water, and then brine, was dried over magnesium sulfate, was filtered, and was concentrated in vacuo.
  • the residue was dissolved in methylene chloride and was applied to a 6 mL column packed with 1 g of silica-bound p-toluene sulfonic acid (Silicycle).
  • the column was eluted by gravity with 2 column volumes (cv) of methylene chloride, 3 cv of methanol to remove reaction by-products, then was eluted with 4 cv of 1 N triethylamine in methanol to remove the product.
  • Example 2 7-methoxy-6-r3-(1 -methyl- 1 H-benzimidazol-2-ylbropoxyl-4-(3- phenylpiperidin-1-vn ⁇ uinazoline: Using Preparation 2 and 3-(1-methyl-1H-benzo[d]imidazol-2- yl)propan-1-ol, the general procedure in Example 1 was used for the synthesis of the title compound in 49% yield; 13C NMR (100 MHz, CD3OD) ⁇ ppm 163.838, 155.478, 154.670, 152.031 , 147.971 , 147.746, 143.312, 141.480, 135.632, 128.671 , 127.100, 126.891 , 122.651 , 122.404, 118.112, 111.001 , 109.648, 105.894, 105.064, 67.803, 56.624, 55.861 , 50.432, 43.104, 32.149,
  • Example 5 7-methoxy-4-(3-phenylpiperidin-1 -yl)-6-IY3-quinolin-2-ylprop-2-yn-1 - vDoxylquinazoline: 2-lodoquinoline (240 mg, 0.94 mmol) was mixed with Preparation 3 (350 mg, 0.94 mmol), copper(l) iodide (23 mg, 0.12 mmol), dichloropalladium bis(triphenylphosine) (23 mg, 0.033 mmol), triethylamine (2 mL), diisopropylamine (2 mL) in chloroform (2 mL) and methanol (2 mL). The mixture was stirred at room temperature for 24 h.
  • Example 6 7-methoxy-4-(3-phenylpiperidin-1 -yl)-6-(3-quinolin-2- ylpropoxy)quinazoline:
  • Example 5 50 mg, 0.1 mmol was mixed with Raney nickel (20 mg) in ethylacetate (10 ml). The mixture was placed under 50 psi hydrogen and was shaken at room temperature for 4 h.
  • Preparation 6 methyl 5-hvdroxy-4-methoxy-2-nitrobenzoate: Preparation 5 (15 g, 70.4 mmol) in methanol (100 mL) was treated with concentrated sulfuric acid (10 mL). The mixture was heated at reflux for 48 h. After cooling to room temperature, the methanol was removed under reduced pressure, the resulting residue was diluted with water and was extracted with ethylacetate. The organic layer was washed with water and then brine, was dried over magnesium sulfate, was filtered, and was concentrated to afford 15.4 g (96% yield) of the title compound; MS (AP/CI): 228 (M+H)+; 226 (M-H)-.
  • Preparation 8 methyl 2-amino-5-(benzyloxy)-4-methoxybenzoate: Preparation 7 (20 g, 63 mmol) was mixed with ammonium chloride (50.6 g, 945 mmol) in methanol (200 mL) and water (50 mL), then iron poiser (35.3 g, 630 mmol) was added and the mixture was heated at 9O 0 C for 24 h. The mixture was filtered while hot through Celite and the filter cake was washed with methylene chloride and water. The aqueous and organic layers were separated and the aqueous layer was made basic with sodium bicarbonate and was extracted with methylene chloride.
  • Preparation 11 6-(benzyloxy)-4-chloro-7-methoxyquinazoline: Preparation 10 (4.85 g, 17.2 mmol) in phosphorous oxychioride (25 mL) was heated to 12O 0 C for 3 h. After cooling to room temperature, the phosphorous oxychioride was removed in vacuo, the residue was slowly added to saturated aqueous potassium carbonate and the mixture was stirred until bubbling ceased.
  • Preparation 12 6-(benzyloxy)-7-methoxy-4-phenylquinazoline:
  • Preparation 11 (1 g, 3.3 mmol) was mixed with phenylboronic acid (0.5 g, 4 mmol), Pd 2 (dba) 3 -CHCI 3 (72 mg, 0.07 mmol), tricyclohexyl phosphine (56 mg, 0.2 mmol), and cesium carbonate (1.6 g, 5 mmol) in 1 ,4-dioxane (10 mL) was heated at 100 0 C for 24 h. After cooling to room temperature, solvent was removed in vacuo. The residue was diluted with water and 1N NaOH and was extracted with chloroform.
  • Preparation 14 6-(benzyloxyV7-methoxy-4-(pyridin-4-vQquinazoline: Using 4- (4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine and Preparation 11, the general procedure in Preparation 12 was used to synthesize the title compound in 41% yield; MS (AP/CI): 344.1 (M+H)+.
  • Preparation 15 6-(benzyloxy)-7-methoxy-4-(3-(trifluoromethyl)phenvQquinazoline: Using Preparation 11 and 3-trifluromethylphenyl boronic acid, the general procedure in Preparation 12 was used to prepare the title compound in 65% yield.; MS (AP/CI): 411.0 (M+H)+.
  • Preparation 16 7-methoxy-4-phenylquinazolin-6-ol: Preparation 12 (0.62 g, 1.8 mmol) was added to anisole (3.9 mL, 36 mmol) in trifluoracetic acid (25 mL). The mixture was heated to 75 0 C for 24 h. After cooling, the mixture was concentrated and was purified by silica gel chromatography (50:1 chloroform-methanol) to afford 430 mg (95% yield) of the title compound; MS (AP/CI) 253.1 (M+H)+.
  • Preparation 17 7-methoxy-4-(pyridin-3-v ⁇ quinazolin-6-ol: Using Preparation 13, the general procedure in Preparation 16 was used to prepare the title compound in 94% yield; MS (AP/CI): 254.1 (M+H)+.
  • Preparation 18 7-methoxy-4-(pyridin-4-yl ' )quinazolin-6-ol: Using Preparation 14, the general procedure in Preparation 16 was used to prepare the title compound in 81 % yield.; MS (AP/CI): 254.1 (M+H)+.
  • Example 8 7-methoxy-6-f3-(1-methyl-1 H-benzimidazol-2-vDpropoxy
  • p-TsCI resin Arnaut Labs
  • diisopropyl ethyl amine diisopropyl ethyl amine
  • Example 13 7-methoxy-4-pyridin-3-yl-6-(quinolin-2-ylmethoxy)quinazoline
  • Example 15 7-methoxy-4-phenyl-6-(quinolin-2-ylmethoxy)quinazoline: Using
  • Preparation 21 6-methoxyquinazolin-7-ol: 6,7-Dimethoxyquinazoline (Preparation 20, 2.3 g, 12 mmol) and L-methionine (2.1 g, 14.4 mmol) in methanesulfonic acid (60 mL) was heated as follows: 120 0 C, 1 h; 14O 0 C, 2 h; 145 0 C, 4 h; 120°C, 16 h. More L-methionine (0.5 g) was added and the mixture was heated at 145°C for 6 h and 120 0 C for 16 h.
  • Preparation 23 6-(benzyloxy)-7-methoxy-N,N-dimethylquinazolin-4-amine: Using Preparation 11 and dimethylamine, the general procedure used to synthesize Preparation 22 was used to prepare the title compound in 86% yield.; MS (AP/CI): 310.1 (M+H)+.
  • Preparation 24 6-(benzyloxyVN,N-diethyl-7-methoxyquinazolin-4-amine: Using
  • Preparation 27 6-(benzyloxyV7-methoxy-4-(piperidin-1 -vDquinazoline: Using Preparation 11 and piperidine, the general procedure in Preparation 22 was used to prepare the title compound in 89% yield.; 13C NMR (101 MHz, CHLOROFORM-D) d ppm 24.9, 26.2,
  • Preparation 28 4-(dimethylamino)-7-methoxyquinazolin-6-ol: Using Preparation 23, the general procedure in Preparation 16 was used to prepare the title compound in 99% yield.; MS (AP/CI): 220.2 (M+H)+.
  • Preparation 29 4-(diethylamino)-7-methoxyquinazolin-6-ol: Using Preparation 24, the general procedure in Preparation 16 was used to prepare the title compound in 98% yield.; MS (AP/CI): 248.1 (M+H)+.
  • Preparation 30 4-(azetidin-1-yl)-7-methoxyquinazolin-6-ol: Using Preparation 25, the general procedure in Preparation 16 was used to prepare the title compound in 99% yield.; MS (AP/CI): 232.2 (M+H)+.
  • Preparation 31 7-methoxy-4-fpyrrolidin-1-yl)quinazolin-6-ol: Using Preparation 26, the general procedure in Preparation 16 was used to prepare the title compound in 99% yield.; MS (AP/CI): 246.3 (M+H)+.
  • Preparation 32 7-methoxy-4-(piperidin-1-v ⁇ quinazolin-6-ol: Using Preparation 27, the general procedure in Preparation 16 was used to prepare the title compound in 99% yield.; 13C NMR (101 MHz, METHANOL-D4) d ppm 24.1 , 26.4, 50.8, 56.5, 99.5, 107.0, 109.3, 136.4, 145.7, 147.6, 156.2, 161.2; MS (AP/CI): 260.3 (M+H)+
  • Preparation 33 7-methoxy-4-morpholino ⁇ uinazolin-6-ol: Using Preparation 22, the general procedure in Preparation 16 was used to prepare the title compound in 99% yield.; MS (AP/CI): 262.1 (M+H)+.
  • Preparation 36 6,7-dimethoxy-4-(pyridin-4-yl)quinazoline: Using 4-chloro-6,7- dimethoxyquinazoline and 4-pyridylboronic acid, the general procedure in Preparation 12 was used in the synthesis of the title compound in 33% yield.; MS (AP/Cl): 268.2 (M+H)+.
  • Preparation 37 6-methoxy-4-phenylquinazolin-7-ol:
  • Preparation 34 1.5 g, 5.64 mmol
  • L-methionine 1.0 g, 6.77 mmol
  • methanesulfonic acid 30 mL
  • the mixture was poured onto ice, the pH was adjusted to a range of 7-8 by using sodium hydroxide, and the mixture was extracted with methylene chloride.
  • the organic layer was dried over magnesium sulfate, was filtered, and was concentrated.
  • the residue was purified by silica gel chromatography (chloroform-methanol, 100:1 ), to afford 0.5 g (35% yield) of the title compound.; MS (AP/Cl): 253.2 (M+H)+.
  • Preparation 38 6-methoxy-4-(pyridin-3-v0quinazolin-7-ol: The same general procedure used to synthesize Preparation 7 was employed, with the change of heating temperatures and times as follows: 120°C, 16 h; then 14O 0 C, 4 h. Following work-up, the aqueous phase was extracted continuously with chloroform ("heavier-than-water" continuous extractor used) for two days. The organic layers were combined, solvent was removed under reduced pressure, and the residue was purified by silica gel chromatography (chloroform- methanol, 40:1 ). The final product was obtained in 50% yield.; MS (AP/Cl): 254.2 (M+H)+.
  • Example 27 6-methoxy-4-phenyl-7-(quinolin-2-ylmethoxy)quinazoline: Using Preparation 39 and 2-chloromethylquinoline, the general procedure in Preparation 3 was used
  • Example 31 6-methoxy-4-pyridin-4-yl
  • Example 32 6-methoxy-7-f3-(1-methyl-1 H-benzimidazol-2-ylbropoxyl-4-pyridin-3- ylquinazoline: Using Preparation 38 and 3-(1-methyl-1H-benzo[d]imidazol-2-yl)propan-1-ol, the general procedure in Example 1 was used for the synthesis of the title compound in 75% yield.; 13C NMR (101 MHz, CHLOROFORM-D) d ppm 161.96, 155.55, 154.12, 153.80, 151.28, 150.93, 150.31 , 149.47, 137.28, 135.89, 133.91 , 123.98, 122.48, 122.25, 119.30, 118.98, 109.20, 108.17, 103.18, 68.32, 56.26, 29.91 , 26.73, 23.98; MS (AP/CI): 426.3 (M+H)+ ;
  • Preparation 40 6-(benzyloxy)-4-chloroquinazoline: The title compound was prepared in a manner analogous to that described for Preparation 11 , using 5-hydroxy-2-nitrobenzoic acid as the starting material in the sequence. MS (AP/CI): 271.1 , 273.1 (M+H)+.
  • Preparation 41 6-(benzyloxy)-4-phenyl ⁇ uinazoline: Using Preparation 40 and phenyl boronic acid, the general procedure in Preparation 12 was used to synthesize the title compound in 48% yield. MS (AP/CI): 313.1 (M+H)+.
  • Preparation 42 6-(benzyloxy)-4-(pyridin-3-yl)quinazoline: Using 3- (diethylboryl)pyridine and Preparation 40, the general procedure in Preparation 12 was used to synthesize the title compound in 30% yield. MS (AP/CI): 314.1 (M+H)+.
  • Preparation 43 6-(benzyloxy)-4-(pyridin-4-yl)quinazoline: Using 4-(4,4,5,5- tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine and Preparation 40, the general procedure in Preparation 12 was used to synthesize the title compound in 41% yield. MS (AP/CI): 314.1 (M+H)+.
  • Preparation 40 and 3-acetylphenyl boronic acid the general procedure in Preparation 12 was used to synthesize the title compound in 72% yield.
  • Preparation 48 4-(pyridin-4-yl)quinazolin-6-ol: Using Preparation 43, the general procedure in Preparation 16 was used to synthesize the title compound in 86% yield. MS (AP/CI): 224.1 (M+H)+.
  • Preparation 49 4-(3-(trifluoromethyl)phenyl)quinazolin-6-ol: Using Preparation 44, the general procedure in Preparation 16 was used to synthesize the title compound in 87% yield. MS (AP/CI): 291.0 (M+H)+.
  • Preparation 50 i-O-fe-hydroxyquinazolin ⁇ -vDphenvOethanone: Using Preparation 45, the general procedure in Preparation 16 was used to synthesize the title compound in 95% yield. MS (AP/CI): 265.1 (M+H)+.
  • Example 35 4-phenyl-6-(quinolin-2-ylmethoxy)quinazoline: Using Preparation 46 and 2-chloromethylquinoline, the general procedure in Preparation 3 was used for the synthesis of the title compound in 81% yield.
  • Example 36 4-pyridin-4-yl-6-(quinolin-2-ylmethoxykiuinazoline: Using Preparation 48 and 2-chloromethylquinoline, the general procedure in Preparation 3 was used for the synthesis of the title compound in 81 % yield.
  • Example 39 1 -(3-r6-(quinolin-2-ylmethoxy)quinazolin-4-v ⁇ phenyl ⁇ ethanol: A solution of Example 38 (100 mg, 0.25 mmol) in methanol (2 mL) at O 0 C was treated with sodium borohydride (19 mg, 0.5 mmol). The mixture was warmed to room temperature and was stirred for 2h. The solvent was removed in vacuo, the residue was diluted with ethyl acetate and was washed with brine, was dried (magnesium sulfate), was filtered, and was concentrated. Purification by silica gel chromatography (chloroform-methanol, 50:1 ), gave 100 mg (98% yield) of the title compound.
  • Example 40 2- ⁇ 3-f6-(quinolin-2-ylmethoxy)quinazolin-4-v ⁇ phenyl ⁇ propan-2-ol: A solution of Example 38 (100 mg, 0.25 mmol) in THF (2 mL) at -40 0 C was treated dropwise with MeMgBr (0.27 mL, 0.375 mmol, 1.4 M in toluene/THF (3:1)). The mixture was stirred at - 4O 0 C for 1h, O 0 C for 3h, was cooled back to -4O 0 C and additional MeMgBr solution (0.4 mL) was added and the mixture was stirred at O 0 C for 2h.
  • MeMgBr 0.27 mL, 0.375 mmol, 1.4 M in toluene/THF (3:1)
  • Example 41 4-phenyl-6-(2-quinolin-2-ylethoxy)quinazoline: Using Preparation 46 and Preparation 4, the general procedure in Example 1 was used for the synthesis of the title compound in 32% yield.
  • 13C NMR (101 MHz 1 CHLOROFORM-D) d ppm 38.7 (s, 1 C) 67.9 (s, 1 C) 105.3 (s, 1 C) 122.3 (s, 1 C) 124.3 (s, 1 C) 126.4 (s, 1 C) 127.0 (s, 1 C) 127.8 (s, 1 C) 129.0 (s, 1 C) 129.8 (s, 1 C) 129.9 (s, 1 C) 130.1 (s, 1 C) 130.5 (s, 1 C) 136.8 (s, 1 C) 137.6 (s, 1 C) 147.5 (s, 1 C) 148.1 (s, 1 C) 153.1 (s, 1 C) 157.9 (s, 1 C) 158.9 (
  • Example 43 4-pyridin-3-yl-6-(2-quinolin-2-ylethoxy)quinazoline: Using Preparation 47 and Preparation 4, the general procedure in Example 1 was used for the synthesis of the title compound in 47% yield.
  • 13C NMR (101 MHz, CHLOROFORM-D) d ppm 38.6 (s, 1 C) 68.0 (s, 1 C) 104.4 (s, 1 C) 122.2 (s, 1 C) 124.3 (s, 1 C) 126.4 (s, 1 C) 127.2 (s, 1 C) 127.4 (s, 1 C) 127.8 (s, 1 C) 129.0 (s, 1 C) 129.9 (s, 1 C) 130.8 (s, 1 C) 136.9 (s, 1 C) 137.2 (s, 1 C) 147.6 (s, 1 C) 148.0 (s, 1 C) 150.4 (s, 1 C) 151.0 (s, 1 C) 153.1 (s, 1 C) 158.3 (
  • Example 44 6-(2-quinolin-2-ylethoxy)-4-f3-(trifluoromethyl)phenvnquinazoline: Using Preparation 49 and Preparation 4, the general procedure in Example 1 was used for the synthesis of the title compound in 45% yield.
  • Preparation 51 7-fluoroquinazolin-4(3H)-one: A mixture of 2-amino-4-fluorobenzoic acid (1.5 g, 9.4 mmol) and formamidine acetate (2.Og, 18.8 mmol) in ethyleneglycol monomethyl ether (15 mL) was heated at 13O 0 C for 24 h. After cooling to room temperature, ca. half of the solvent was evaporated and a white solid precipitated. Aqueous ammmonia (2 mL of 30% ammonium hydroxide in 20 mL water) was added and the solid was filtered, was washed with water, was washed with hexanes, and was dried in vacuo to give 1.4 g (91% yield) of the title compound. MS (AP/CI): 165.2 (M+H)+.
  • Preparation 52 7-(benzyloxy)quinazolin-4(3H)-one: Sodium hydride (60% dispersion, 0.3 g, 7.3 mmol) was added to a solution of benzyl alcohol (0.76 mL, 7.3 mmol) in dimethylformamide (DMF 1 8 mL). Preparation 51 (300 mg, 1.8 mmol) was added and the mixture was heated to 140 0 C for 4 h. After cooling to room temperature, concentrated hydrochloric acid was added, which afforded a precipitate.
  • DMF 1 8 mL dimethylformamide
  • Preparation 54 7-(benzyloxy)-4-phenylquinazoline: Using Preparation 53 and 4- phenylboronic acid, the procedure in Preparation 12 afforded the title compound in 50% yield.
  • Preparation 57 7-(benzyloxy)-4-(4-methoxyphenyl)quinazoline: Using Preparation 53 and 4-methoxyphenylboronic acid, following the procedure in Preparation 12 afforded the title compound in 45% yield. MS (AP/CI): 343.3 (M+H)+.
  • Preparation 58 7-(benzyloxy)-4-(3-methoxyphenyl ' )quinazoline: Using Preparation 53 and 3-methoxyphenylboronic acid, following the procedure in Preparation 12 afforded the title compound in 51% yield. MS (AP/CI): 343.4 (M+H)+.
  • Preparation 59 4-phenylquinazolin-7-ol: A mixture of Preparation 54 (0.55 g, 1.76 mmol) and 10% palladium on carbon (100 mg), in methanol (20 mL) was placed under 50 psi hydrogen and was shaken for 24 h at room temperature. The mixture was filtered through
  • Preparation 60 4-(pyridin-3-vQquinazolin-7-ol: Using Preparation 55 and the general procedure from Preparation 16, the title compound was prepared in 77% yield. MS (AP/CI): 224.2 (M+H)+.
  • Preparation 61 4-(pyridin-4-v ⁇ uinazolin-7-ol: Using the mixture from Preparation 56 and the general procedure from Preparation 16, the title compound was prepared in 4% yield over two steps. MS (AP/CI): 224.2 (M+H)+.
  • Preparation 62 4-(3-methoxyphenyl)quinazolin-7-ol: Using Preparation 58, the general procedure in Preparation 59 was used to prepare the title compound in 30% yield. MS (AP/CI): 253.3 (M+H)+.
  • Preparation 63 4-(4-methoxyphenv0 ⁇ uinazolin-7-ol: Using Preparation 57, the general procedure in Preparation 59 was used to prepare the title compound in 22% yield. MS (AP/CI): 253.3 (M+H)+.
  • Example 45 4-pyridin-4-yl-7-(quinolin-2-ylmethoxy)quinazoline: Using Preparation
  • Example 46 4-phenyl-7-( ⁇ uinolin-2-ylmethoxy) ⁇ uinazoline: Using Preparation 59 and 2-chloromethylquinoline, the general procedure in Preparation 3 was used for the synthesis of the title compound in 58% yield.
  • Example 48 4-(3-methoxyphenyl)-7-(quinolin-2-ylrnethoxy)quinazoline: Using Preparation 62 and 2-chloromethylquinoline, the general procedure in Preparation 3 was used for the synthesis of the title compound in 60% yield.
  • Example 49 4-(4-methoxyphenyl)-7-(quinolin-2-ylmethoxy)quinazoline: Using Preparation 63 and 2-chloromethylquinoline, the general procedure in Preparation 3 was used for the synthesis of the title compound in 85% yield.
  • Preparation 65 6-hvdroxy-7-methoxy-3-(2,2,2-trifluoroethyl)quinazolin-4(3H)-one: Using Preparation 64, the general procedure in Preparation 16 was used to prepare the title compound in 81% yield. MS (AP/CI): 275.0 (M+H)+.
  • Preparation 66 6-(benzyloxy)-3-ethyl-7-metho ⁇ yquinazolin-4(3H)-one: Using ethylamine, the general procedure in Preparation 64 was used to prepare the title compound in 40% yield. MS (AP/CI): 311.1 (M+H)+.
  • Preparation 67 3-ethyl-6-hvdroxy-7-metho ⁇ yquinazolin-4(3H)-one: Using Preparation 66, the general procedure in Preparation 16 was used to prepare the title compound in 72% yield. MS (AP/CI): 221.1 (M+H)+ ;l.
  • Preparation 68 6-(benzyloxyV3-isobutyl-7-methoxyquinazolin-4(3H)-one: Using isobutylamine, the general procedure in Preparation 64 was used to prepare the title compound in 16% yield. MS (AP/CI): 339.1 (M+H)+.
  • Preparation 70 6-(benzyloxy)-3-cvclopropyl-7-methoxyquinazolin-4(3H)-one: Using cyclopropylamine, the general procedure in Preparation 64 was used to prepare the title compound in 81 % yield. MS (AP/CI): 323.0 (M+H)+.
  • Preparation 71 3-cvclopropyl-6-hvdroxy-7-methoxyquinazolin-4(3H)-one: Using
  • Preparation 70 the general procedure in Preparation 16 was used to prepare the title compound in 86% yield. MS (AP/CI): 233.1 (M+H)+.
  • Preparation 72 6-(benzyloxy)-7-methoxy-3-(2-methoxyethv ⁇ quinazolin-4(3H)-one: Using 2-methoxyethylamine, the general procedure in Preparation 64 was used to prepare the title compound in 27% yield. MS (AP/CI): 341.1 (M+H)+.
  • Preparation 74 2-amino-4,5-dimethoxy-N-methylbenzamide: Methylamine (15 mL, 30 mmol, 2 M in THF) and 2-amino-4,5-dimethoxybenzoic acid in DMF (15 mL) were treated with 1-hydroxybenzotriazole (4.3g, 31.5 mmol) and dicyclohexylcarbodiimide (6.5 g, 31.5 mmol). After stirring at room temperature for 24 h, the existing solid was filtered offand was washed with chloroform. The filtrate was concentrated, was diluted with ethyl acetate, and the solution was washed with aqueous sodium bicarbonate, then was extracted with 2N HCI.
  • Methylamine 15 mL, 30 mmol, 2 M in THF
  • 2-amino-4,5-dimethoxybenzoic acid in DMF 15 mL
  • 1-hydroxybenzotriazole 4.3g, 31.5 mmol
  • Preparation 77 the general procedure in Preparation 16 was used to prepare the title compound in 95% yield. MS (AP/CI): 261.1 (M+H)+ .
  • Preparation 79 6-(benzyloxy)-3-isopropyl-7-methoxyquinazolin-4(3H)-one: Using isopropylamine the general procedure in Preparation 64 was used used to prepare the title compound in 50% yield. MS (AP/CI): 325.0 (M+H)+.
  • Preparation 80 6-hvdroxy-3-isopropyl-7-methoxyquinazolin-4(3H)-one: Using
  • Example 51 3-ethyl-7-methoxy-6-(2-quinolin-2-ylethoxy)quinazolin-4(3H)-one: Using Preparation 67 and Preparation 4, the general procedure in Example 1 was used for the synthesis of the title compound in 64% yield. Diagnostic 13C NMR signals (101 MHz, CHLOROFORM-D) d ppm 15.2 (s, 1 C) 38.6 (s, 1 C) 42.3 (s, 1 C) 56.4 (s, 1 C) 61.6 (s, 1 C)
  • Example 52 3-isobutyl-7-methoxy-6-(2-quinolin-2-ylethoxy)quinazolin-4(3H)-one: Using Preparation 69 and Preparation 4, the general procedure in Example 1 was used for the synthesis of the title compound in 66% yield.
  • Example 53 3-cvclopropyl-7-methoxy-6-(2-quinolin-2-ylethoxy)quinazolin-4(3H)- one: Using Preparation 71 and Preparation 4, the general procedure in Example 1 was used for the synthesis of the title compound in 34% yield.
  • Example 56 3-cvclopentyl-7-methoxy-6-(2-quinolin-2-ylethoxy)quinazolin-4(3H)- one: Using Preparation 78 and Preparation 4, the general procedure in Example 1 was used for the synthesis of the title compound in 56% yield.
  • Example 58 7-methoxy-3-methyl-6-r3-( 1 -methyl-1 H-benzimidazol-2- yl)propoxylquinazolin-4(3H)-one: Using Preparation 76 and 3-(1-methyl-1 H-benzo[d]imidazol- 2-yl)propan-1-ol, the general procedure in Example 1 was used for the synthesis of the title compound in 37% yield.
  • Example 59 3-cvclobutyl-7-methoxy-6-(2-quinolin-2-ylethoxy)quinazolin-4(3H)- one: Using Preparation 82 and Preparation 4, the general procedure in Example 1 was used for the synthesis of the title compound in 50% yield. 13C NMR (101 MHz, CHLOROFORM- D) d ppm 15.5 (s, 1 C) 30.0 (s, 1 C) 38.5 (s, 1 C) 50.3 (s, 1 C) 56.4 (s, 1 C) 68.5 (s, 1 C)
  • Example 61 2-r2-(quinolin-6-yloxy)ethyllquinoline: Using 6-hydroxyquinoline and Preparation 4, the general procedure in Example 1 was used for the synthesis of the title compound in 15% yield.; 13C NMR (101 MHz, CHLOROFORM-D) d ppm 38.8 (s, 1 C) 67.7 (s, 1 C) 106.4 (s, 1 C) 121.5 (s, 1 C) 122.3 (s, 1 C) 122.9 (s, 1 C) 126.4 (s, 1 C) 127.2 (s, 1 C) 127.8 (s, 1 C) 128.9 (s, 1 C) 129.5 (s, 1 C) 129.9 (s, 1 C) 130.8 (s, 1 C) 135.3 (s, 1 C) 136.9 (s, 1 C) 148.0 (s, 1 C) 157.2 (s, 1 C) 159.1 (s, 1 C); MS (AP/CI): 301.3 (M+H)+ ; IC 50
  • Example 62 7-f3-(1-methyl-1 H-benzimidazol-2-yl)propoxy1quinoline: Using 7- hydroxyquinoline and 3-(1-methyl-1 H-benzo[d]imidazol-2-yl)propan-1-ol, the general procedure in Example 1 was used for the synthesis of the title compound in 35% yield.; 13C NMR (101 MHz, CHLOROFORM-D) d ppm 24.1 (s, 1 C) 27.2 (s, 1 C) 29.9 (s, 1 C) 67.2 (s, 1 C) 108.4 (s, 1 C) 109.2 (s, 1 C) 119.3 (s, 1 C) 120.0 (s, 1 C) 122.2 (s, 1 C) 122.4 (s, 1 C) 123.8 (s, 1 C) 129.1 (s, 1 C) 135.9 (s, 1 C) 136.0 (s, 1 C) 142.5 (s, 1 C) 150.0 (s, 1 C) 150.7 (s
  • Example 64 7-r3-(1-methyl-1 H-benzimidazol-2-yl)propoxy[isoquinoline: Using 7- hydroxyisoquinoline and 3-(1-methyl-1 H-benzo[d]imidazol-2-yl)propan-1-ol, the general procedure in Example 1 was used for the synthesis of the title compound in 28% yield.; 13C NMR (101 MHz, CHLOROFORM-D) d ppm 24.0 (s, 1 C) 27.1 (s, 1 C) 29.9 (s, 1 C) 67.2 (s, 1 C) 105.9 (s, 1 C) 109.3 (s, 1 C) 119.2 (s, 1 C) 120.4 (s, 1 C) 122.3 (s, 1 C) 122.5 (s, 1 C) 123.8 (s, 1 C) 128.3 (s, 1 C) 130.0 (s, 1 C) 131.6 (s, 1 C) 135.9 (s, 1 C) 141.4 (s, 1 C) 14
  • Example 65 6-f3-(1 -methyl-1 H-benzimidazol-2-yl)propoxy1auinoline: Using 6- hydroxyquinoline and 3-(1-methyl-1H-benzo[d]imidazol-2-yl)propan-1-ol, the general procedure in Example 1 was used for the synthesis of the title compound in 28% yield.; 13C NMR (101 MHz, CHLOROFORM-D) d ppm 24.0 (s, 1 C) 27.1 (s, 1 C) 29.9 (s, 1 C) 67.1 (s, 1 C) 106.2 (s, 1 C) 109.3 (s, 1 C) 119.2 (s, 1 C) 121.6 (s, 1 C) 122.3 (s, 1 C) 122.6 (s, 1 C) 129.5 (s, 1 C) 131.1 (s, 1 C) 135.1 (s, 1 C) 135.8 (s, 1 C) 142.2 (s, 1 C) 144.6 (s, 1 C) 148.2 (s, 1

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés hétéro-aromatiques servant d'inhibiteurs efficaces de phosphodiestérase (PDE). L'invention conerne également des composés qui sont des inhibiteurs sélectifs de PDE10. L'invention concerne en outre des intermédiaires pour la préparation de tels composés, des compositions pharmaceutiques comprenant de tels composés, ainsi que l'utilisation de tels composés dans des procédés de traitement de certains troubles du système nerveux central (CNS) ou autres. L'invention concerne de plus des procédés de traitement de troubles neurodégénératifs et psychiatriques, par exemple la psychose et des troubles ayant comme symptôme un déficit de cognition.
PCT/IB2007/002382 2006-08-17 2007-08-16 Composés hétéro-aromatiques à base de quinoline WO2008020302A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82265106P 2006-08-17 2006-08-17
US60/822,651 2006-08-17

Publications (2)

Publication Number Publication Date
WO2008020302A2 true WO2008020302A2 (fr) 2008-02-21
WO2008020302A3 WO2008020302A3 (fr) 2008-04-17

Family

ID=38910921

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002382 WO2008020302A2 (fr) 2006-08-17 2007-08-16 Composés hétéro-aromatiques à base de quinoline

Country Status (1)

Country Link
WO (1) WO2008020302A2 (fr)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073444A2 (fr) 2009-12-18 2011-06-23 Basf Se Azolines dans la lutte contre les nuisibles invertébrés
JP2011520969A (ja) * 2008-05-19 2011-07-21 シェーリング コーポレイション 二環式ヘテロ環誘導体およびｇｐｒ１１９モジュレーターとしてのその使用
WO2011131741A1 (fr) 2010-04-21 2011-10-27 Boehringer Ingelheim International Gmbh Amides d'acide carboxylique hétérocycliques comme inhibiteurs de pdk1
WO2011143495A1 (fr) * 2010-05-13 2011-11-17 Amgen Inc. Composés d'hétéroaryloxyhétérocyclyle convenant comme inhibiteurs de la pde10
EP2435048A1 (fr) * 2009-05-29 2012-04-04 Merck Sharp & Dohme Corp. Inhibiteurs de pde10 radio-marqués
WO2012062319A1 (fr) 2010-11-10 2012-05-18 H. Lundbeck A/S Ligands radiomarqués à base de phénylimidazole
WO2012112946A1 (fr) 2011-02-18 2012-08-23 Allergan, Inc. Dérivés de 6,7-dialkoxy-3-isoquinolinol substitués en tant qu'inhibiteurs de la phosphodiestérase 10 (pde10a)
US20120283436A1 (en) * 2011-05-03 2012-11-08 The University Of Houston Facile preparation of 4-substituted quinazolines and related heterocycles
WO2013000994A1 (fr) 2011-06-30 2013-01-03 Abbott Gmbh & Co. Kg Nouveaux composés inhibiteurs de la phosphodiestérase de type 10a
WO2013035826A1 (fr) * 2011-09-08 2013-03-14 武田薬品工業株式会社 Composé hétérocyclique fusionné
CN103038229A (zh) * 2010-05-26 2013-04-10 桑诺维恩药品公司 杂芳基化合物及其使用方法
WO2013068489A1 (fr) 2011-11-09 2013-05-16 Abbott Gmbh & Co. Kg Carboxamides hétérocycliques utiles comme inhibiteurs de la phosphodiestérase de type 10a
WO2013068470A1 (fr) 2011-11-09 2013-05-16 Abbott Gmbh & Co. Kg Inhibiteurs de la phosphodiestérase de type 10a
WO2014027078A1 (fr) 2012-08-17 2014-02-20 AbbVie Deutschland GmbH & Co. KG Composés inhibiteurs de la phosphodiestérase de type a10
WO2014071044A1 (fr) 2012-11-01 2014-05-08 Allergan, Inc. Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a)
WO2014079995A2 (fr) 2012-11-26 2014-05-30 Abbvie Inc. Nouveaux composés inhibiteurs de phosphodiestérase de type 10a
CN103874701A (zh) * 2011-09-09 2014-06-18 H.隆德贝克有限公司 吡啶化合物和其用途
WO2014140184A1 (fr) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Nouveaux composés inhibiteurs de la phosphodiestérase de type 10a
WO2014039714A3 (fr) * 2012-09-06 2014-10-02 Plexxikon Inc. Composés et procédés pour la modulation des kinases, et leurs indications
WO2014210168A1 (fr) * 2013-06-25 2014-12-31 The Trustees Of Columbia University In The City Of New York Activation ou réactivation de l'ache
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
US9388180B2 (en) 2012-09-17 2016-07-12 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2016151144A1 (fr) * 2015-03-25 2016-09-29 Pierre Fabre Medicament Dérivés de quinazoline substitués utilisés en tant qu'inhibiteurs de l'adn-méthyltransférase
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9790232B2 (en) 2013-11-01 2017-10-17 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9827248B2 (en) 2013-02-15 2017-11-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9833453B2 (en) 2013-02-20 2017-12-05 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10125117B2 (en) 2013-01-15 2018-11-13 The Trustees Of Columbia University In The City Of New York Activation or reactivation of ache
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2020021064A1 (fr) 2018-07-26 2020-01-30 Domain Therapeutics Dérivés de quinazolinone substitués et leur utilisation en tant que modulateurs allostériques positifs de mglur4
WO2020065583A1 (fr) 2018-09-28 2020-04-02 Takeda Pharmaceutical Company Limited Balipodect pour traiter ou prévenir des troubles du spectre autistique
CN111065626A (zh) * 2017-06-05 2020-04-24 Ptc医疗公司 用于治疗亨廷顿氏舞蹈病的化合物
US10766907B2 (en) 2016-09-08 2020-09-08 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
US12139499B2 (en) 2018-06-27 2024-11-12 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
JP7620629B2 (ja) 2019-12-02 2025-01-23 アカデミア シニカ ＰＤＩＡ４阻害剤及びβ細胞発症機序を阻害し、糖尿病を治療するためのこのＰＤＩＡ４阻害剤の使用

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956371A (en) * 1989-09-19 1990-09-11 Euroceltique, S.A. Substituted isoquinolines and methods of using same
EP0787725A1 (fr) * 1994-10-20 1997-08-06 Nippon Chemiphar Co., Ltd. Derive de quinoline
WO1997030034A1 (fr) * 1996-02-14 1997-08-21 Zeneca Limited Derives de la quinazoline servant d'agents antitumoraux
WO2001012187A2 (fr) * 1999-08-18 2001-02-22 Astrazeneca Ab Composes chimiques
EP1153920A1 (fr) * 1999-01-22 2001-11-14 Kirin Beer Kabushiki Kaisha Derives de quinoline et derives de quinazoline
WO2002000644A1 (fr) * 2000-06-24 2002-01-03 Astrazeneca Ab Derives guanidiniques de la quinazoline et de la quinoleine utilises dans le traitement de maladies auto-immunes
WO2002094789A1 (fr) * 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Derives de la quinoleine utilises comme ligands pour le recepteur y de neuropeptide
EP1300464A1 (fr) * 2000-07-07 2003-04-09 Eisai Co., Ltd. Gene de synthese de la paroi des cellules fongiques
WO2004006846A2 (fr) * 2002-07-15 2004-01-22 Exelixis, Inc. Modulateurs de kinase de type recepteur et procedes d'utilisation
US20050137395A1 (en) * 2003-12-23 2005-06-23 Agouron Pharmaceuticals, Inc. Novel quinoline derivatives
WO2005120514A1 (fr) * 2004-06-07 2005-12-22 Pfizer Products Inc. Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique
WO2006070284A1 (fr) * 2004-12-31 2006-07-06 Pfizer Products Inc. Derives de pyrrolidyle de composes heteroaromatiques utilises en tant qu'inhibiteurs de phosphodiesterase

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956371A (en) * 1989-09-19 1990-09-11 Euroceltique, S.A. Substituted isoquinolines and methods of using same
EP0787725A1 (fr) * 1994-10-20 1997-08-06 Nippon Chemiphar Co., Ltd. Derive de quinoline
WO1997030034A1 (fr) * 1996-02-14 1997-08-21 Zeneca Limited Derives de la quinazoline servant d'agents antitumoraux
EP1153920A1 (fr) * 1999-01-22 2001-11-14 Kirin Beer Kabushiki Kaisha Derives de quinoline et derives de quinazoline
WO2001012187A2 (fr) * 1999-08-18 2001-02-22 Astrazeneca Ab Composes chimiques
WO2002000644A1 (fr) * 2000-06-24 2002-01-03 Astrazeneca Ab Derives guanidiniques de la quinazoline et de la quinoleine utilises dans le traitement de maladies auto-immunes
EP1300464A1 (fr) * 2000-07-07 2003-04-09 Eisai Co., Ltd. Gene de synthese de la paroi des cellules fongiques
WO2002094789A1 (fr) * 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Derives de la quinoleine utilises comme ligands pour le recepteur y de neuropeptide
WO2004006846A2 (fr) * 2002-07-15 2004-01-22 Exelixis, Inc. Modulateurs de kinase de type recepteur et procedes d'utilisation
US20050137395A1 (en) * 2003-12-23 2005-06-23 Agouron Pharmaceuticals, Inc. Novel quinoline derivatives
WO2005120514A1 (fr) * 2004-06-07 2005-12-22 Pfizer Products Inc. Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique
WO2006070284A1 (fr) * 2004-12-31 2006-07-06 Pfizer Products Inc. Derives de pyrrolidyle de composes heteroaromatiques utilises en tant qu'inhibiteurs de phosphodiesterase

Cited By (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520969A (ja) * 2008-05-19 2011-07-21 シェーリング コーポレイション 二環式ヘテロ環誘導体およびｇｐｒ１１９モジュレーターとしてのその使用
EP2435048A4 (fr) * 2009-05-29 2013-07-10 Merck Sharp & Dohme Inhibiteurs de pde10 radio-marqués
EP2435048A1 (fr) * 2009-05-29 2012-04-04 Merck Sharp & Dohme Corp. Inhibiteurs de pde10 radio-marqués
US8846000B2 (en) 2009-05-29 2014-09-30 Merck Sharp & Dohme Corp. Radiolabeled PDE10 inhibitors
JP2012528176A (ja) * 2009-05-29 2012-11-12 メルク・シャープ・エンド・ドーム・コーポレイション 放射標識されたｐｄｅ１０阻害剤
WO2011073444A2 (fr) 2009-12-18 2011-06-23 Basf Se Azolines dans la lutte contre les nuisibles invertébrés
WO2011131741A1 (fr) 2010-04-21 2011-10-27 Boehringer Ingelheim International Gmbh Amides d'acide carboxylique hétérocycliques comme inhibiteurs de pdk1
WO2011143495A1 (fr) * 2010-05-13 2011-11-17 Amgen Inc. Composés d'hétéroaryloxyhétérocyclyle convenant comme inhibiteurs de la pde10
US9376450B2 (en) 2010-05-13 2016-06-28 Amgen Inc. Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
US8497265B2 (en) 2010-05-13 2013-07-30 Amgen Inc. Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
CN103038229A (zh) * 2010-05-26 2013-04-10 桑诺维恩药品公司 杂芳基化合物及其使用方法
US10562916B2 (en) 2010-05-26 2020-02-18 Sunovion Pharmaceuticals, Inc. Substituted quinoxalines as PDE-10 inhibitors
EP2576540A2 (fr) * 2010-05-26 2013-04-10 Sunovion Pharmaceuticals Inc. Composés hétéroarylés et leurs procédés d'utilisation
AU2011258217B2 (en) * 2010-05-26 2016-12-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
EP3318561A1 (fr) * 2010-05-26 2018-05-09 Sunovion Pharmaceuticals Inc. Composés hétéroaryles et procédés d'utilisation correspondants
US9834564B2 (en) 2010-05-26 2017-12-05 Sunovion Pharmaceuticals Inc. Substituted quinolines as PDE-10 inhibitors
EP2576540A4 (fr) * 2010-05-26 2013-12-04 Sunovion Pharmaceuticals Inc Composés hétéroarylés et leurs procédés d'utilisation
WO2012062319A1 (fr) 2010-11-10 2012-05-18 H. Lundbeck A/S Ligands radiomarqués à base de phénylimidazole
US9670181B2 (en) 2011-02-18 2017-06-06 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US8772316B2 (en) 2011-02-18 2014-07-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
WO2012112946A1 (fr) 2011-02-18 2012-08-23 Allergan, Inc. Dérivés de 6,7-dialkoxy-3-isoquinolinol substitués en tant qu'inhibiteurs de la phosphodiestérase 10 (pde10a)
US20120283436A1 (en) * 2011-05-03 2012-11-08 The University Of Houston Facile preparation of 4-substituted quinazolines and related heterocycles
US9273012B2 (en) * 2011-05-03 2016-03-01 University Of Houston System Facile preparation of 4-substituted quinazolines and related heterocycles
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2013000994A1 (fr) 2011-06-30 2013-01-03 Abbott Gmbh & Co. Kg Nouveaux composés inhibiteurs de la phosphodiestérase de type 10a
WO2013035826A1 (fr) * 2011-09-08 2013-03-14 武田薬品工業株式会社 Composé hétérocyclique fusionné
CN103874701A (zh) * 2011-09-09 2014-06-18 H.隆德贝克有限公司 吡啶化合物和其用途
US10308610B2 (en) 2011-11-09 2019-06-04 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
WO2013068489A1 (fr) 2011-11-09 2013-05-16 Abbott Gmbh & Co. Kg Carboxamides hétérocycliques utiles comme inhibiteurs de la phosphodiestérase de type 10a
WO2013068470A1 (fr) 2011-11-09 2013-05-16 Abbott Gmbh & Co. Kg Inhibiteurs de la phosphodiestérase de type 10a
JP2014534976A (ja) * 2011-11-09 2014-12-25 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー ホスホジエステラーゼ１０ａ型の阻害薬
US9856220B2 (en) 2011-11-09 2018-01-02 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
WO2014027078A1 (fr) 2012-08-17 2014-02-20 AbbVie Deutschland GmbH & Co. KG Composés inhibiteurs de la phosphodiestérase de type a10
US9464085B2 (en) 2012-08-17 2016-10-11 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
WO2014039714A3 (fr) * 2012-09-06 2014-10-02 Plexxikon Inc. Composés et procédés pour la modulation des kinases, et leurs indications
US10227357B2 (en) 2012-09-06 2019-03-12 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9388180B2 (en) 2012-09-17 2016-07-12 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2014071044A1 (fr) 2012-11-01 2014-05-08 Allergan, Inc. Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a)
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3610890A1 (fr) 2012-11-14 2020-02-19 The Johns Hopkins University Procédés et compositions de traitement de la schizophrénie
US10624875B2 (en) 2012-11-14 2020-04-21 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2014079995A2 (fr) 2012-11-26 2014-05-30 Abbvie Inc. Nouveaux composés inhibiteurs de phosphodiestérase de type 10a
US10125117B2 (en) 2013-01-15 2018-11-13 The Trustees Of Columbia University In The City Of New York Activation or reactivation of ache
US10398703B2 (en) 2013-02-15 2019-09-03 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9877970B2 (en) 2013-02-15 2018-01-30 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10966987B2 (en) 2013-02-15 2021-04-06 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9827248B2 (en) 2013-02-15 2017-11-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10285991B2 (en) 2013-02-20 2019-05-14 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9861634B2 (en) 2013-02-20 2018-01-09 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US11369611B2 (en) 2013-02-20 2022-06-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10758539B2 (en) 2013-02-20 2020-09-01 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9833453B2 (en) 2013-02-20 2017-12-05 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
US9163019B2 (en) 2013-03-14 2015-10-20 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
US9475808B2 (en) 2013-03-14 2016-10-25 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
WO2014140184A1 (fr) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Nouveaux composés inhibiteurs de la phosphodiestérase de type 10a
WO2014210168A1 (fr) * 2013-06-25 2014-12-31 The Trustees Of Columbia University In The City Of New York Activation ou réactivation de l'ache
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9790232B2 (en) 2013-11-01 2017-10-17 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US11713323B2 (en) 2013-11-01 2023-08-01 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10160765B2 (en) 2013-11-01 2018-12-25 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10975090B2 (en) 2013-11-01 2021-04-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10618906B2 (en) 2013-11-01 2020-04-14 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US9902710B2 (en) 2013-12-05 2018-02-27 Exonhit Therapeutics, Sa Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US10450299B2 (en) 2015-03-25 2019-10-22 Centre National De La Recherche Scientifique (Cnrs) Substituted quinazoline derivatives as DNA methyltransferase inhibitors
WO2016151144A1 (fr) * 2015-03-25 2016-09-29 Pierre Fabre Medicament Dérivés de quinazoline substitués utilisés en tant qu'inhibiteurs de l'adn-méthyltransférase
US11021487B2 (en) 2016-09-08 2021-06-01 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10766907B2 (en) 2016-09-08 2020-09-08 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10626121B2 (en) 2016-09-08 2020-04-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US11104685B2 (en) 2016-09-08 2021-08-31 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN111065626A (zh) * 2017-06-05 2020-04-24 Ptc医疗公司 用于治疗亨廷顿氏舞蹈病的化合物
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
US12139499B2 (en) 2018-06-27 2024-11-12 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
WO2020021064A1 (fr) 2018-07-26 2020-01-30 Domain Therapeutics Dérivés de quinazolinone substitués et leur utilisation en tant que modulateurs allostériques positifs de mglur4
WO2020065583A1 (fr) 2018-09-28 2020-04-02 Takeda Pharmaceutical Company Limited Balipodect pour traiter ou prévenir des troubles du spectre autistique
JP7620629B2 (ja) 2019-12-02 2025-01-23 アカデミア シニカ ＰＤＩＡ４阻害剤及びβ細胞発症機序を阻害し、糖尿病を治療するためのこのＰＤＩＡ４阻害剤の使用

Also Published As

Publication number Publication date
WO2008020302A3 (fr) 2008-04-17

Similar Documents

Publication Publication Date Title
WO2008020302A2 (fr) Composés hétéro-aromatiques à base de quinoline
EP1841757B1 (fr) Composes de quinoline heteroaromatiques et leur utilisation comme inhibiteurs de pde-10
US20090176829A1 (en) Bicyclic heteroaryl compounds as pde10 inhibitors
US20090023756A1 (en) Substituted quinazolines as pde10 inhibitors
US20070155779A1 (en) Bicyclic heteroaryl compounds as pde10 inhibitors
WO2008001182A1 (fr) Composés hétéroaryliques tricycliques comme inhibiteurs de pde10
EP1838702A1 (fr) Derives de pyrrolidyle de composes heteroaromatiques utilises en tant qu'inhibiteurs de phosphodiesterase
US20100222353A1 (en) Aminophthalazine derivative compounds
EP1773805A1 (fr) Derives quinazolin-4-yl- piperidine et cinnolin-4-yl-piperidine utilises en tant qu'inhibiteurs de pde10 pour le traitement de troubles du snc
EP2057141A1 (fr) Composés de pyrimidone en tant qu'inhibiteurs de gsk-3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07789654

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07789654

Country of ref document: EP

Kind code of ref document: A2